Karyopharm Therapeutics Inc.KPTINASDAQ
LOADING
|||
Switch Symbol:
Operating Income Growth Accelerating
Trending higher, above historical average, modest growth trend.
Left:
||||
Year-over-year operating income growth rate
Latest
37.59%
↑ 11848% above average
Average (39q)
0.31%
Historical baseline
Range
High:207.19%
Low:-173.65%
CAGR
+5.7%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | 37.59% |
| Q2 2025 | 26.67% |
| Q1 2025 | -6.31% |
| Q4 2024 | -19.02% |
| Q3 2024 | 6.53% |
| Q2 2024 | 16.70% |
| Q1 2024 | 10.71% |
| Q4 2023 | -20.95% |
| Q3 2023 | -5.70% |
| Q2 2023 | 4.29% |
| Q1 2023 | 8.77% |
| Q4 2022 | -9.83% |
| Q3 2022 | 28.13% |
| Q2 2022 | -24.06% |
| Q1 2022 | -173.65% |
| Q4 2021 | 207.19% |
| Q3 2021 | 10.68% |
| Q2 2021 | 6.35% |
| Q1 2021 | -41.30% |
| Q4 2020 | 21.32% |
| Q3 2020 | -16.84% |
| Q2 2020 | 14.86% |
| Q1 2020 | -9.45% |
| Q4 2019 | -9.81% |
| Q3 2019 | 5.48% |
| Q2 2019 | 35.79% |
| Q1 2019 | -13.00% |
| Q4 2018 | -16.89% |
| Q3 2018 | -43.17% |
| Q2 2018 | 11.84% |
| Q1 2018 | 1.29% |
| Q4 2017 | -27.04% |
| Q3 2017 | -4.38% |
| Q2 2017 | 1.74% |
| Q1 2017 | -11.46% |
| Q4 2016 | -5.53% |
| Q3 2016 | 15.53% |
| Q2 2016 | -11.43% |
| Q1 2016 | 6.67% |
| Q4 2015 | 4.27% |